Figure 1From: Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02) Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin ® (HD IL-2) and Ipilimumab Yervoy ® ) in patients with metastatic melanoma (proclivity 02) Back to article page